VivoSeq
Other

Feeding Intolerance

0

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

Feeding Intolerance is an early-stage landscape with 0 programs across 3 companies. The most active players are Menarini, Lyric Pharmaceuticals, Takeda.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

71/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Menarini logo

Menarini

0 programs

PreclinicalL

Lyric Pharmaceuticals

0 programs

PreclinicalTakeda logo

Takeda

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

12

clinical trials

Unknown status5 · 42%
Completed5 · 42%
Terminated2 · 17%

Clinical Trials

Trial Activity

12 trials

Preliminary Efficacy, Safety and Pharmacokinetics Study of Nepadutant in Infant With Feeding Intolerance
Completed·Menarini logoMenarini·Phase 2·NCT01532518·27 enrolled
SAFEstart Feeding Intolerance Study Phase II
Completed·IIntermountain Health Care, Inc.·Phase 2·NCT00331201·20 enrolled
Efficacy, Safety, and Pharmacokinetics (PK) Study of Ulimorelin in Patients With Enteral Feeding Intolerance (EFI): The PROMOTE Trial
Completed·LLyric Pharmaceuticals·Phase 2·NCT02784392·120 enrolled
Multi-Center Study of Different Doses Domperidone in Feeding Intolerance
Completed·NNanfang Hospital, Southern Medical University·Phase 4·NCT02980250·118 enrolled
Electrogastrography (EGC) in Premature Infants With Feeding Intolerance
Completed·NNational Center for Research Resources (NCRR)·Phase 2·NCT00008736
Efficacy of Prophylactic Glycerin Suppositories for Feeding Intolerance in Very Low Birth Weight Preterm Infants: a Randomized Trial
Terminated·KKing Faisal Specialist Hospital & Research Center·N/A·NCT01799629·220 enrolled
TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)
Terminated·Takeda logoTakeda·Phase 2·NCT03477903·1 enrolled
The Effect of β-Carotene, Vitamin D3 and Zinc on Hyaline Membrane Disease and Feeding Intolerance in Premature Neonates
Unknown status·IIndonesia University·Phase 4·NCT03366584·120 enrolled
Influence of Bovine Lactoferrin on Feeding Intolerance and Intestinal Permeability in Preterm Neonates
Unknown status·MMansoura University Children Hospital·Phase 1·NCT04738058·60 enrolled
Itopride in Feeding Intolerance of Critically-ill Patients Receiving Enteral Nutrition
Unknown status·—·N/A·NCT03698292·60 enrolled
Glycerin Suppositories for Treatment of Feeding Intolerance in Preterm Infants
Unknown status·KKing Saud Medical City·N/A·NCT02149407·230 enrolled
Lactated Ringer's Solution in Neonates With Feeding Intolerance
Unknown status·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 2·NCT01236833·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)